A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Nevens, Frederik; Andreoné, Pietro; Mazzella, G.; I. Strasser, Simone; L. Bowlus, Christopher; Invernizzi, Pietro; P.H. Drenth, Joost; J. Pockros, Paul; Reguła, Jarosław; Beuers, Ulrich; Trauner, Michael; Jones, David; Floreani, Annarosa; Hohenester, Simon; A. Luketic, Velimir; L. Shiffman, Mitchell; J. van Erpecum, Karel; Vargas, Vı́ctor; Vincent, Catherine; M. Hirschfield, Gideon; Shah, Hemant; E. Hansen, Bettina; D. Lindor, Keith; Marschall, Hanns–Ulrich; V. Kowdley, Kris; Hooshmand-Rad, Roya; Marmon, Tonya; Sheeron, Shawn; Pencek, Richard; MacConell, Leigh; Pruzanski, Mark; А. Шапиро, Д.

doi:10.1056/nejmoa1509840

Public

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Published in New England Journal of Medicine • Aug 17, 2016

Authors:

Frederik Nevens

Pietro Andreoné

G. Mazzella

Abstract

BACKGROUND: Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy. Alkaline phosphatase and bilirubin levels correlate with the risk of liver transplantation or death. Obeticholic acid, a farnesoid X receptor agonist, has...

Subject

Obeticholic acid

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!